Get access

Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab

Authors

  • Ariel M. Burns,

    Corresponding author
    1. Department of Medicine, Division of Dermatology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada
      Ariel M. Burns, Department of Medicine, Division of Dermatology, Dalhousie University, 4th Floor, Dickson Bldg, 5820 University Ave, Halifax, Nova Scotia, B3H 1V7, Canada
      Tel: +(902) 473 2814
      Fax: +(902) 473 2655
      e-mail: arielburns@hotmail.com
    Search for more papers by this author
  • Peter J. Green,

    1. Department of Medicine, Division of Dermatology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada
    Search for more papers by this author
  • Sylvia Pasternak

    1. Department of Laboratory Medicine, Division of Anatomical Pathology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada
    Search for more papers by this author

Ariel M. Burns, Department of Medicine, Division of Dermatology, Dalhousie University, 4th Floor, Dickson Bldg, 5820 University Ave, Halifax, Nova Scotia, B3H 1V7, Canada
Tel: +(902) 473 2814
Fax: +(902) 473 2655
e-mail: arielburns@hotmail.com

Abstract

A 59-year-old female with rheumatoid arthritis on etanercept therapy presented with a 7-cm-large subcutaneous forearm mass. Multiple smaller nodules subsequently developed on the upper and lower extremities. Except for a new cough, the patient was systemically well. Biopsy of the mass showed sarcoidal type granulomatous inflammation with nodular aggregations of non-necrotizing epithelioid histiocytes in the subcutis. A chest computed tomography (CT) scan showed mediastinal adenopathy consistent with pulmonary sarcoidosis. Etanercept was discontinued, and the patient was started on adalimumab for rheumatoid arthritis control. The cutaneous nodules fully resolved in 6 months with no additional treatment. A 4-month follow-up CT scan showed significant regression of mediastinal adenopathy. The patient has since been maintained on adalimumab therapy for 2 years with no recurrence of sarcoid-like manifestations. Biologic response modifiers targeting tumor necrosis factor alpha (TNFα) are effective treatments of chronic inflammatory conditions such as rheumatoid arthritis and psoriasis. TNFα represents a major cytokine in granuloma formation, and TNFα inhibitors are sometimes efficacious in the treatment of sarcoidosis. Paradoxically, there is a small volume of literature implicating TNFα inhibitors in the development of sarcoid-like disease. We present this case to promote the recognition of TNFα inhibitor-induced sarcoidosis and to illustrate the wide clinicopathologic differential of sarcoidal type granulomas.

Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab.

Get access to the full text of this article

Ancillary